Compare Stocks: ANIX, EDIT, ELYM, and EPRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.18	$3.10	$2.32 ▼ $5.46	$108.18M	0.55	236,344 shs	107,787 shs
EDIT Editas Medicine	$2.82	$2.89	$1.66 ▼ $4.54	$433.10M	2.14	1.48 million shs	1.47 million shs
ELYM Eliem Therapeutics	$16.33 +10.9%	$12.60	$2.35 ▼ $11.55	$485.85M	-0.39	486,688 shs	2.50 million shs
EPRX Eupraxia Pharmaceuticals	$6.72	$6.43	$5.04 ▼ $9.32	$436.93M	1.08	381,185 shs	164,660 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	0.00%	-7.02%	-6.47%	+15.22%	+7.07%
EDIT Editas Medicine	0.00%	-2.08%	-5.37%	+11.46%	-6.93%
ELYM Eliem Therapeutics	0.00%	+16.64%	+29.81%	+51.20%	+759.47%
EPRX Eupraxia Pharmaceuticals	0.00%	-0.74%	+1.97%	+0.45%	+26.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.18	$3.10	$2.32 ▼ $5.46	$108.18M	0.55	236,344 shs	107,787 shs
EDIT Editas Medicine	$2.82	$2.89	$1.66 ▼ $4.54	$433.10M	2.14	1.48 million shs	1.47 million shs
ELYM Eliem Therapeutics	$16.33 +10.9%	$12.60	$2.35 ▼ $11.55	$485.85M	-0.39	486,688 shs	2.50 million shs
EPRX Eupraxia Pharmaceuticals	$6.72	$6.43	$5.04 ▼ $9.32	$436.93M	1.08	381,185 shs	164,660 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	0.00%	-7.02%	-6.47%	+15.22%	+7.07%
EDIT Editas Medicine	0.00%	-2.08%	-5.37%	+11.46%	-6.93%
ELYM Eliem Therapeutics	0.00%	+16.64%	+29.81%	+51.20%	+759.47%
EPRX Eupraxia Pharmaceuticals	0.00%	-0.74%	+1.97%	+0.45%	+26.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	2.80	Moderate Buy	$8.50	167.30% Upside
EDIT Editas Medicine	2.50	Moderate Buy	$5.40	91.49% Upside
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	2.89	Moderate Buy	$18.00	167.86% Upside

Current Analyst Ratings Breakdown

Latest ANIX, EDIT, ELYM, and EPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	EPRX Eupraxia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
6/30/2026	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
6/25/2026	EPRX Eupraxia Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
6/17/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/12/2026	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/12/2026	ANIX Anixa Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/27/2026	EDIT Editas Medicine	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	515.16	N/A	N/A	$0.42 per share	7.57
EDIT Editas Medicine	$40.52M	10.69	N/A	N/A	$0.28 per share	10.07
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$10.93M	-$0.31	N/A	N/A	N/A	N/A	-71.12%	-62.88%	9/9/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	N/A
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	N/A	N/A	N/A	-47.03%	-45.97%	N/A
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.02	N/A	N/A	N/A	N/A	-63.97%	-43.32%	11/3/2026 (Estimated)

Latest ANIX, EDIT, ELYM, and EPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q3 2026	ANIX Anixa Biosciences	-$0.08	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	-$0.23	+$0.02	-$0.23	N/A	N/A
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million
6/10/2026	Q2 2026	ANIX Anixa Biosciences	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	9.79	9.79
EDIT Editas Medicine	N/A	3.19	3.19
ELYM Eliem Therapeutics	N/A	60.41	60.41
EPRX Eupraxia Pharmaceuticals	0.02	16.00	16.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
EDIT Editas Medicine	71.90%
ELYM Eliem Therapeutics	69.76%
EPRX Eupraxia Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	26.40%
EDIT Editas Medicine	3.10%
ELYM Eliem Therapeutics	4.70%
EPRX Eupraxia Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	34.02 million	25.04 million	Optionable
EDIT Editas Medicine	230	153.58 million	148.82 million	Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
EPRX Eupraxia Pharmaceuticals	29	65.02 million	N/A	N/A

ANIX, EDIT, ELYM, and EPRX Headlines

Recent News About These Companies

Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Stifel Nicolaus

August 14 at 8:56 AM | theglobeandmail.com

Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful ...

August 13, 2026 | finanznachrichten.de

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic ...

August 13, 2026 | theglobeandmail.com

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

August 13, 2026 | globenewswire.com

Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 12, 2026 | finanznachrichten.de

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Earnings Results

August 11, 2026 | marketbeat.com

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 11, 2026 | financialpost.comF

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 11, 2026 | globenewswire.com

Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?

August 10, 2026 | zacks.com

Eupraxia Pharmaceuticals (EPRX) Expected to Release Quarterly Earnings on Tuesday

August 10, 2026 | americanbankingnews.com

EUPRAXIA PHARMACEUTICALS INC (EPRX.NE)

August 6, 2026 | ca.finance.yahoo.com

Eupraxia Pharmaceuticals (EPRX) to Post Earnings on Tuesday

August 4, 2026 | marketbeat.com

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 3, 2026 | marketbeat.com

Seven Fleet Capital Management LP Acquires New Position in Eupraxia Pharmaceuticals Inc. $EPRX

August 2, 2026 | marketbeat.com

276,000 Shares in Eupraxia Pharmaceuticals Inc. $EPRX Acquired by DV Trading LLC

August 2, 2026 | marketbeat.com

700,000 Shares in Eupraxia Pharmaceuticals Inc. $EPRX Acquired by Redmile Group LLC

July 29, 2026 | marketbeat.com

Ally Bridge Group NY LLC Raises Stock Holdings in Eupraxia Pharmaceuticals Inc. $EPRX

July 29, 2026 | marketbeat.com

Rubric Capital Management LP Takes $5 Million Position in Eupraxia Pharmaceuticals Inc. $EPRX

July 28, 2026 | marketbeat.com

Affinity Asset Advisors LLC Has $11.50 Million Holdings in Eupraxia Pharmaceuticals Inc. $EPRX

July 25, 2026 | marketbeat.com

Cantor Fitzgerald Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

July 22, 2026 | theglobeandmail.com

Why Eupraxia Pharmaceuticals Inc.’s (EPRX) Stock Is Up 5.03%

July 17, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANIX, EDIT, ELYM, and EPRX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.18 0.00 (0.00%)

As of 08/14/2026 04:00 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Editas Medicine NASDAQ:EDIT

$2.82 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.82 +0.01 (+0.18%)

As of 08/14/2026 07:34 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Eliem Therapeutics NASDAQ:ELYM

$16.33 +1.60 (+10.86%)

As of 08/14/2026

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$6.72 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$6.82 +0.11 (+1.56%)

As of 08/14/2026 07:37 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIX, EDIT, ELYM, and EPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIX, EDIT, ELYM, and EPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIX, EDIT, ELYM, and EPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANIX, EDIT, ELYM, and EPRX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Editas Medicine NASDAQ:EDIT

Eliem Therapeutics NASDAQ:ELYM

Eupraxia Pharmaceuticals NASDAQ:EPRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIX, EDIT, ELYM, and EPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIX, EDIT, ELYM, and EPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIX, EDIT, ELYM, and EPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANIX, EDIT, ELYM, and EPRX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Editas Medicine NASDAQ:EDIT

Eliem Therapeutics NASDAQ:ELYM

Eupraxia Pharmaceuticals NASDAQ:EPRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools